In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 201 to 225 of 388

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237]	Technology appraisal guidance	6 August 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	NICE guideline	2 December 2026
Middle meningeal artery embolisation for chronic subdural haematomas	Interventional procedures guidance	19 November 2026
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]	Technology appraisal guidance	3 September 2026
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]	Technology appraisal guidance	7 May 2026
Monofocal intraocular lenses for cataract surgery	Health technology evaluation	10 March 2027
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]	Technology appraisal guidance	TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Multidisciplinary care of children and young people with achondroplasia	NICE review	29 April 2926
Nemolizumab for treating prurigo nodularis [ID6451]	Technology appraisal guidance	10 June 2026
Neonatal infection: antibiotics for prevention and treatment - update	NICE guideline	13 May 2026
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]	Technology appraisal guidance	9 September 2026
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]	Technology appraisal guidance	TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]	Technology appraisal guidance	28 June 2017
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance	TBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]	Technology appraisal guidance	TBC
Nirogacestat for treating desmoid tumours [ID6453]	Technology appraisal guidance	10 June 2026
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]	Technology appraisal guidance	17 July 2024
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]	Technology appraisal guidance	TBC
Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]	Technology appraisal guidance	TBC
Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]	Technology appraisal guidance	11 November 2026
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]	Technology appraisal guidance	TBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]	Technology appraisal guidance	TBC

Results per page

10
25
50
All